Recurrent disease in renal allografts

Area of Science:

• Pediatric Nephrology
• Transplantation Immunology
• Genetics

Background:

• Recurrent or de novo diseases constitute 5% of pediatric graft failure, providing valuable insights into underlying mechanisms.
• Metabolic diseases like type I hyperoxaluria are notable for recurrence after transplantation.
• Various forms of nephritis can histologically recur in allografts, with differing clinical significance.

Purpose of the Study:

• To review the mechanisms and clinical impact of recurrent and de novo diseases in pediatric kidney allografts.
• To highlight specific conditions with high recurrence rates and their implications for transplant outcomes.
• To discuss the challenges in managing these diseases and the limited effectiveness of current treatments.

Main Methods:

• Literature review of pediatric kidney transplant cases with recurrent or de novo graft diseases.
• Analysis of disease-specific recurrence rates and clinical manifestations.
• Evaluation of treatment strategies and their outcomes.

Main Results:

• Type I hyperoxaluria recurrence necessitates combined liver-renal transplantation or prophylactic liver transplantation.
• Focal segmental glomerulosclerosis (FSGS) and Membranous Glomerulonephritis type I (MCGN type I) recur with high frequency and severity.
• While some nephritides (e.g., MCGN type II, IgA nephropathy) show mild or no clinical recurrence, others like anti-GBM nephritis in Alport syndrome often lead to graft failure.
• De novo membranous nephropathy occurs in up to 10% of pediatric grafts, typically with mild or no clinical impact.

Conclusions:

• Understanding recurrent and de novo diseases is crucial for improving pediatric kidney transplant outcomes.
• Specific conditions like type I hyperoxaluria, FSGS, and MCGN type I pose significant risks due to high recurrence rates.
• Further research is needed to identify risk factors and develop effective treatments for these challenging post-transplant complications.